Trends in A1C Concentrations Among U.S. Adults With Diagnosed Diabetes From 1999 to 2004

Ford, Earl S.; Li, Chaoyang; Little, Randie R.; Mokdad, Ali H.

doi:10.2337/dc07-0565

Cited by 92 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The long-acting basal insulin analogs, insulin glargine (IGlar) and insulin detemir, mimic endogenous basal insulin action more closely than human insulin preparations, such as neutral protamine Hagedorn (NPH) insulin, and they are associated with lower rates of hypoglycemia 9 , a major barrier to the timely introduction and effective use of insulin 10 . However, despite these and other advances in diabetes management, many patients remain unable to meet the recommended levels of glycemic control [11][12][13][14] . Therefore, there continues to be a need for basal insulins with improved pharmacokinetic and pharmacodynamic properties that would allow more patients to reach and maintain glycemic targets at an even lower risk of hypoglycemia.…”

Section: Introductionmentioning

confidence: 99%

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

Onishi

Iwamoto

Yoo

et al. 2013

J of Diabetes Invest

143

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

Onishi

Iwamoto

Yoo

et al. 2013

J of Diabetes Invest

143

View full text Add to dashboard Cite

show abstract

“…There is, moreover, an unmet need for new anti-diabetic medications, justifying the twostep approach to ruling out cardiovascular risk. For example, a recent publication showed that approximately 45% of adults with diagnosed diabetes are not at the American Diabetes Association HbA1c target of <7% despite the widespread availability of multiple classes of antidiabetic medications [25]. Although there may be many reasons for the low proportion of patients meeting HbA1c goals, the limitations of current therapies may play a role [26].…”

Section: Defining Unacceptable Cardiovascular Riskmentioning

confidence: 98%

Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus

Joffe

Parks

Temple

2010

Rev Endocr Metab Disord

View full text Add to dashboard Cite

All medications currently approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus are indicated to improve glycemic control. Since 1995, FDA has used HbA1c as the primary basis for approval of these therapies because a reduction in blood glucose lessens the symptoms of hyperglycemia and lowering of HbA1c has been shown to reduce the risk for some of the chronic complications of diabetes. Despite evidence of clinical benefit with therapies that reduce HbA1c, concerns have been raised that some diabetes medications may increase cardiovascular risk in a patient population that is already vulnerable to cardiovascular disease. Therefore, FDA convened a public advisory committee meeting to discuss the role of cardiovascular assessment in the pre-approval and post-approval settings for medications developed for the treatment of type 2 diabetes. After considering the advisory panel's recommendations and other data, FDA published a guidance document requesting evidence showing that new treatments for type 2 diabetes do not result in an unacceptable increase in cardiovascular risk. This review article begins by summarizing the events leading up to publication of this guidance. Subsequent sections discuss the guidance itself as well as general considerations for implementing the new cardiovascular recommendations. The new approach to developing medications for the treatment of type 2 diabetes will lead to evaluation in patients more representative of those who will use these therapies, if approved, and will help healthcare providers make informed decisions when choosing a medication within the growing treatment armamentarium for type 2 diabetes.

show abstract

“…Increases in glycaemic control and guideline adherence have been found in other studies. [22][23][24] Moreover, increased educational efforts aimed at both physicians and people with diabetes may also explain these trends. Future studies will need to explore these findings in more detail in order to verify whether specific characteristics of patients, medical conditions and physicians influence the effectiveness of interventions based on computer-generated laboratory data.…”

Section: Limitationsmentioning

confidence: 99%

Effectiveness of an HbA1c tracking tool on primary care management of diabetes mellitus: glycaemic control, clinical practice and usability

Howard

Sommers²,

Gould³

et al. 2009

Journal of Innovation in Health Informatics

View full text Add to dashboard Cite

Trends in A1C Concentrations Among U.S. Adults With Diagnosed Diabetes From 1999 to 2004

Cited by 92 publications

References 21 publications

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus

Effectiveness of an HbA1c tracking tool on primary care management of diabetes mellitus: glycaemic control, clinical practice and usability

Contact Info

Product

Resources

About